Blue Note Pharmaceuticals

Blue Note Therapeutics is a prescription digital therapeutics company dedicated to easing the psychological burden of cancer and improving patient outcomes. The company develops software-based treatments designed to address the anxiety, depression, and distress that frequently accompany a cancer diagnosis. By digitizing evidence-based interventions such as cognitive behavioral therapy, Blue Note provides accessible and scalable mental health support integrated directly into the oncology care continuum. Their lead product, attune, is designed for patients with various forms of cancer-related distress and has received FDA Breakthrough Device Designation. The company's pipeline also includes specialized programs for patients with acute myeloid leukemia and other high-stress medical conditions.